Microbiology and Immunology

You are here

Home > Publications > Publications

Publications

Found 429 results
Author Title Type [ Year(Desc)]
Filters: First Letter Of Last Name is D  [Clear All Filters]
2024
Juste MAntoine Je, Joseph Y, Lespinasse D, Apollon A, Jamshidi P, Lee MHee, Ward M, Brill E, Duffus Y, Chukwukere U et al..  2024.  People Living With HIV Have More Intact HIV DNA in Circulating CD4+ T Cells if They Have History of Pulmonary Tuberculosis.. Pathog Immun. 9(2):172-193.
Juste MAntoine Je, Joseph Y, Lespinasse D, Apollon A, Jamshidi P, Lee MHee, Ward M, Brill E, Duffus Y, Chukwukere U et al..  2024.  People Living With HIV Have More Intact HIV DNA in Circulating CD4+ T Cells if They Have History of Pulmonary Tuberculosis.. Pathog Immun. 9(2):172-193.
Juste MAntoine Je, Joseph Y, Lespinasse D, Apollon A, Jamshidi P, Lee MHee, Ward M, Brill E, Duffus Y, Chukwukere U et al..  2024.  People Living With HIV Have More Intact HIV DNA in Circulating CD4+ T Cells if They Have History of Pulmonary Tuberculosis.. Pathog Immun. 9(2):172-193.
Hviid L, Jensen AR, Deitsch KW.  2024.  PfEMP1 and var genes - Still of key importance in Plasmodium falciparum malaria pathogenesis and immunity.. Adv Parasitol. 125:53-103.
Dupnik K, Rivera VR, Dorvil N, Duffus Y, Akbarnejad H, Gao Y, Liu J, Apollon A, Dumont E, Riviere C et al..  2024.  Potential Utility of C-reactive Protein for Tuberculosis Risk Stratification Among Patients With Non-Meningitic Symptoms at HIV Diagnosis in Low- and Middle-income Countries.. Open Forum Infect Dis. 11(7):ofae356.
Dupnik K, Rivera VR, Dorvil N, Duffus Y, Akbarnejad H, Gao Y, Liu J, Apollon A, Dumont E, Riviere C et al..  2024.  Potential Utility of C-reactive Protein for Tuberculosis Risk Stratification Among Patients With Non-Meningitic Symptoms at HIV Diagnosis in Low- and Middle-income Countries.. Open Forum Infect Dis. 11(7):ofae356.
Dupnik K, Rivera VR, Dorvil N, Duffus Y, Akbarnejad H, Gao Y, Liu J, Apollon A, Dumont E, Riviere C et al..  2024.  Potential Utility of C-reactive Protein for Tuberculosis Risk Stratification Among Patients With Non-Meningitic Symptoms at HIV Diagnosis in Low- and Middle-income Countries.. Open Forum Infect Dis. 11(7):ofae356.
Dupnik K, Rivera VR, Dorvil N, Duffus Y, Akbarnejad H, Gao Y, Liu J, Apollon A, Dumont E, Riviere C et al..  2024.  Potential Utility of C-reactive Protein for Tuberculosis Risk Stratification Among Patients With Non-Meningitic Symptoms at HIV Diagnosis in Low- and Middle-income Countries.. Open Forum Infect Dis. 11(7):ofae356.
Singh A, Ottavi S, Krieger I, Planck K, Perkowski A, Kaneko T, Davis AM, Suh C, Zhang D, Goullieux L et al..  2024.  Redirecting raltitrexed from cancer cell thymidylate synthase to Mycobacterium tuberculosis phosphopantetheinyl transferase.. Sci Adv. 10(11):eadj6406.
Mansfield CR, Quan B, Chirgwin ME, Eduful B, Hughes PF, Neveu G, Sylvester K, Ryan DH, Kafsack BFC, Haystead TAJ et al..  2024.  Selective targeting of Plasmodium falciparum Hsp90 disrupts the 26S proteasome.. Cell Chem Biol. 31(4):729-742.e13.
Yu Z, Dong X, Song M, Xu A, He Q, Li H, Ouyang W, Chouchane L, Ma X.  2024.  Targeting UBR5 inhibits postsurgical breast cancer lung metastases by inducing CDC73 and p53 mediated apoptosis.. Int J Cancer. 154(4):723-737.
Hahn WO, K Parks R, Shen M, Ozorowski G, Janes H, Ballweber-Fleming L, Davis ASWoodward, Duplessis C, Tomai M, Dey AK et al..  2024.  Use of 3M-052-AF with Alum adjuvant in HIV trimer vaccine induces human autologous neutralizing antibodies.. J Exp Med. 221(10)
Hahn WO, K Parks R, Shen M, Ozorowski G, Janes H, Ballweber-Fleming L, Davis ASWoodward, Duplessis C, Tomai M, Dey AK et al..  2024.  Use of 3M-052-AF with Alum adjuvant in HIV trimer vaccine induces human autologous neutralizing antibodies.. J Exp Med. 221(10)
Hahn WO, K Parks R, Shen M, Ozorowski G, Janes H, Ballweber-Fleming L, Davis ASWoodward, Duplessis C, Tomai M, Dey AK et al..  2024.  Use of 3M-052-AF with Alum adjuvant in HIV trimer vaccine induces human autologous neutralizing antibodies.. J Exp Med. 221(10)
Hahn WO, K Parks R, Shen M, Ozorowski G, Janes H, Ballweber-Fleming L, Davis ASWoodward, Duplessis C, Tomai M, Dey AK et al..  2024.  Use of 3M-052-AF with Alum adjuvant in HIV trimer vaccine induces human autologous neutralizing antibodies.. J Exp Med. 221(10)
Hahn WO, K Parks R, Shen M, Ozorowski G, Janes H, Ballweber-Fleming L, Davis ASWoodward, Duplessis C, Tomai M, Dey AK et al..  2024.  Use of 3M-052-AF with Alum adjuvant in HIV trimer vaccine induces human autologous neutralizing antibodies.. J Exp Med. 221(10)
Bosch B, DeJesus MA, Schnappinger D, Rock JM.  2024.  Weak links: Advancing target-based drug discovery by identifying the most vulnerable targets.. Ann N Y Acad Sci. 1535(1):10-19.
2025
Yang Z, Zhang L, Ottavi S, Geri JB, Perkowski A, Jiang X, Pfau D, Bryk R, Aubé J, Zimmerman M et al..  2025.  ACOD1-mediated lysosomal membrane permeabilization contributes to Mycobacterium tuberculosis-induced macrophage death.. Proc Natl Acad Sci U S A. 122(12):e2425309122.
Du Y, Faz-Lopez B, Kioon MDominique, Cenac C, Pierides M, Lakin KS, Spiera RF, Chaumeil J, Truchetet M-E, Gordon JK et al..  2025.  Altered X-chromosome inactivation of the TLR7/8 locus and heterogeneity of pDCs in systemic sclerosis.. J Exp Med. 222(3)
Mishra S, Singh PRanjan, Hu X, Lopez-Quezada L, Jinich A, Jahn R, Geurts L, Shen N, DeJesus MA, Hartman T et al..  2025.  Candidate transmission survival genome of Mycobacterium tuberculosis.. Proc Natl Acad Sci U S A. 122(10):e2425981122.
Mishra S, Singh PRanjan, Hu X, Lopez-Quezada L, Jinich A, Jahn R, Geurts L, Shen N, DeJesus MA, Hartman T et al..  2025.  Candidate transmission survival genome of Mycobacterium tuberculosis.. Proc Natl Acad Sci U S A. 122(10):e2425981122.
Truong A, Hu R, Quan B, Bailey MA, Schroeder EA, Sylvester K, Neveu G, Kafsack BFC, Fitzgerald MC, Derbyshire ER.  2025.  Covalent inhibition of Plasmodium falciparum Ubc13 impairs global protein synthesis.. iScience. 28(6):112545.
Davis SH, Mathieson M, Buchanan KI, Dawson A, Smith A, Cocco M, Tamaki FK, Post JM, Baragaña B, Jansen C et al..  2025.  Design and Development of Lysyl tRNA Synthetase Inhibitors, for the Treatment of Tuberculosis.. J Med Chem. 68(15):16459-16482.
Davis SH, Mathieson M, Buchanan KI, Dawson A, Smith A, Cocco M, Tamaki FK, Post JM, Baragaña B, Jansen C et al..  2025.  Design and Development of Lysyl tRNA Synthetase Inhibitors, for the Treatment of Tuberculosis.. J Med Chem. 68(15):16459-16482.
Wang X, Su H, Wallach JB, Wagner JC, Braunecker BJ, Gardner M, Guinn KM, Howard NC, Klevorn T, Lin K et al..  2025.  Engineered Mycobacterium tuberculosis triple-kill-switch strain provides controlled tuberculosis infection in animal models.. Nat Microbiol. 10(2):482-494.